CDKN2A and central nervous system cancer: Germane to these genetic alterations, if harboring cyclin dependent kinase inhibitor 2A/B (CDKN2A/B) homozygous deletion, the impact on prognosis of the IDH mutated gliomas equals that of World Health Organization (WHO) grade 4 tumors rendering it of pivotal relevance [10].